Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies

NCT04072458 is registered in ClinicalTrials.gov with Bio-Path Holdings, Inc. as lead sponsor.

NCT NCT04072458
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04072458 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Clinical Trial to Study the Safety, Pharmacokinetics, and Efficacy of BP1002 (L-Bcl-2) Antisense Oligonucleotide in Patients With Advanced Lymphoid Malignancies
Lead sponsor
Bio-Path Holdings, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
November 5, 2020
Completion date
April 30, 2025
Enrollment
30 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), cutaneous t-cell lymphoma (ctcl), dlbcl, follicular lymphoma, hodgkin lymphoma, mantle cell lymphoma, marginal zone lymphoma, peripheral t-cell lymphoma (ptcl), small lymphocytic lymphoma (sll), waldenstrom macroglobulinemia